What's in MeiraGTx UK II Ltd's pipeline?

MeiraGTx UK II Ltd has 4 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with MeiraGTx UK II Ltd's portfolio?

Top competitors by shared drug class: Abeona Therapeutics, Inc, AskBio Inc, BioLab 612 LLC, Brain Neurotherapy Bio, Inc., Emily de los Reyes.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/meiragtx-uk-ii-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

MeiraGTx UK II Ltd — Portfolio Competitive Intelligence Brief

MeiraGTx UK II Ltd pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Ophthalmology · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Abeona Therapeutics, Inc · 1 shared drug class
AskBio Inc · 1 shared drug class
BioLab 612 LLC · 1 shared drug class
Brain Neurotherapy Bio, Inc. · 1 shared drug class
Emily de los Reyes · 1 shared drug class
Eva Morava-Kozicz · 1 shared drug class
Kolon TissueGene, Inc. · 1 shared drug class
4D Molecular Therapeutics · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MeiraGTx UK II Ltd:

Cite this brief

Drug Landscape (2026). MeiraGTx UK II Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/meiragtx-uk-ii-ltd. Accessed 2026-05-16.